Company intelligence / Profile preview

Otic Therapy

Ownership: Private
Development stage: Other

Overview

Otic Pharma developed a nasally-administered combination drug (OP-02) for otitis media and Eustachian tube dysfunction. The lead program aimed to break the cycle of recurrent/chronic otitis media. At the time of its merger with Tokai Pharmaceuticals in late 2016/early 2017, OP-02 had completed Phase I clinical pharmacodynamic studies with plans to move into Phase II development[3].

Therapeutic areas: OtolaryngologyInfectious Diseases
Modalities: Small moleculeCombination drugFoam-based drug delivery
Industry: Biotech

Beyond the preview

Go deeper on Otic Therapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otic Therapy.

Explore the full profile